Gain Therapeutics Stock (NASDAQ:GANX), Trade Ideas

Gain Therapeutics

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ALZN

AZTR

GANX

SILO

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying

Parkinsons disease

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

Gain Therapeutics&#39; GBA1 Parkinson&#39;s disease focused GT-02287&#39;s mechanism of action, tackling GCase misfolding to enhance lysosomal activity.

EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson&#39;s Disease

Small Cap

Intraday Update

Movers

ABVC

AIRE

ANGH

AORT

ATGL

BURL

CENT

COMP

ENTA

FINV

GLMD

GPAK

HIBB

JAGX

MCAF

Morgan Stanley Capital Protected Notes for S&P 500 Index

MRAI

RCEL

SBSW

SKIN

TCOM

TCON

VTVT

XXII

Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results.

Net revenue rose 5% Y/Y to $1.30 billion, beating the consensus of $1.28 billion. EPS of $0.49 surpassed the consensus of $0.48.

Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Gain Therapeutics Inc

A popular asset allocation strategy promoted by hedge funds, including&nbsp;Bridgewater Associates&#8216;&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/ray-dalio" rel="noreferrer noopener">Ray Dalio</a>, is reportedly facing investor redemptions after underperforming promises.
What Happened:&nbsp;Bridgewater and other hedge funds promised superior returns with their &#8220;risk-parity portfolios,&#8221; but after half a decade of subpar performance, investors are pulling their money out, Bloomberg&nbsp;<a target="_blank" href="https://news.bloomberglaw.com/capital-markets/ray-dalios-famous-trade-is-sputtering-and-investors-are-bailing" rel="noreferrer noopener">reported</a>.&nbsp;
Large investors, including public pension funds in New Mexico, Oregon, and Ohio, have withdrawn their investments, leading to a $70 billion decline in these funds from their peak three years ago. This comes despite reassurances from hedge funds that things could improve in the next decade.
Risk parity was successful only during the Great Financial Crisis of 2008-09 and &#8220;that was really its heyday,&#8221; said Eileen Neill, as per the report, whose firm advises New Mexico&#8217;s $17 billion worth of public employee pension.
Since 2019, risk-parity funds have consistently underperformed the standard 60/40 global stock-bond mix, according to a broad industry index, as per the report. This lackluster performance has led to a significant investor exodus, with Verus estimates compiled from eVestment data showing a drop in risk-parity fund assets from a peak of $160 billion in 2021 to roughly $90 billion by the end of 2023.
What Is Risk-Parity?&nbsp;A&nbsp;<a target="_blank" href="https://www.benzinga.com/news/22/09/29068486/2022-made-sure-even-risk-parity-strategies-dont-work-this-etf-lost-over-28-this-year" rel="noreferrer noopener">risk-parity portfolio</a>, according to a University of Massachusetts Amherst paper, &#8220;defines a well-diversified portfolio as one where all asset classes have the same marginal contribution to the total risk of the portfolio.&#8221; This approach prioritizes risk management over chasing high returns and involves portfolio rebalancing and leverage.
Unlike traditional 60/40 stock-to-bond portfolios, risk-parity focuses on risk distribution rather than dollar amounts invested in each asset class.
The risk-parity portfolio was first launched in 1996 to manage Dalio&#8217;s trust assets, as per Bloomberg, and was lauded as a way to &#8220;use deep economic research to craft the best possible portfolio, instead of trying to call the next big thing.&#8221;
Instead of taking on high risk in a bid to chase superior returns, the approach propounded diversification across an array of assets such as commodities and bonds, with each as an equal driver of the portfolio&#8217;s volatility.
See Also:<a target="_blank" href="https://www.benzinga.com/yield-investments" rel="noreferrer noopener">&nbsp;Best High-Yield Investments To Earn</a>
Defenders Of The Strategy:&nbsp;Proponents of the strategy argue that exiting now, with stocks at record highs, is a &#8220;classic investor error.&#8221; Bridgewater claims its &#8220;All Weather&#8221; fund that targets 10% volatility may be underperforming currently, but believes risk-parity remains superior for long-term investing, especially with potential stagnation in stock gains.
The &#8220;All Weather&#8221; iteration fell 22% in 2022, with&nbsp;Michael Markov&nbsp;of Markov Processes<a target="_blank" href="https://www.benzinga.com/news/22/09/29068486/2022-made-sure-even-risk-parity-strategies-dont-work-this-etf-lost-over-28-this-year" rel="noreferrer noopener">&nbsp;blaming the underperformance</a>&nbsp;on it being less reactive to short-term market swings and correlation changes.
Risk-parity funds also face stiff competition from private credit funds and top hedge funds with consistent returns. 
Michael Shackelford, chief investment officer at the Public Employees Retirement Association of New Mexico, reportedly said, &#8220;If I'm going to have 6% or 8% of my portfolio in something else, I'd rather that something else be a bucket of really good performing hedge funds.&#8221;
Investors should focus on future performance, argued&nbsp;Jordan Brooks&nbsp;of&nbsp;AQR Capital Management, whose firm manages $13.7 billion in risk-parity investments. &#8220;It's investors' job at the end of the day not to look backward but forward to what's the best portfolio to navigate the next decade,&#8221; he said.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), an exchange-traded fund that mirrors the S&amp;P 500 Index, ended Monday&#8217;s session up 0.92% at $499.72, according to <a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro</a> data. The RPAR Risk Parity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPAR#NYSE">RPAR</a>) closed the previous session 0.16% lower at $18.63 and is down over 5% over the past year.
Read Next: <a href="https://www.benzinga.com/news/24/01/36647975/2024-win-for-president-joe-biden-or-donald-trump-would-be-threatening-for-markets-ray-dalio-says">2024 Win For President Joe Biden Or Donald Trump Would Be &#8216;Threatening&#8217; For Markets, Ray Dalio Says</a>

Hedge Funds

Media

RPAR

Ray Dalio's Way Loses Shine As Investors Yank Out Billions From Risk-Parity Funds After Disappointing Returns: But Is It A 'Classic Investment Error?'

Macro Economic Events

Econ #s

Economics

Germany Services Purchasing Managers Index Preliminary For April 53.3 Vs. 50.6 Est.; 50.1 Prior

Germany Manufacturing Purchasing Managers Index Preliminary For April 42.2 Vs. 42.8 Est.; 41.9 Prior

Sasol's Nine Months Ended March 31, 2024 Mining Productivity +4% YoY, Gas Production +8% YoY, SO Production Volumes +3% YoY, And Total Chemicals Sales Volumes + 4% YoY

Honda Motor Europe Renews And Expands IT Partnership with Kyndryl Via Multiyear Managed Infrastructure Services Agreement

France Services Purchasing Managers Index Preliminary For April 50.5 Vs. 48.9 Est.; 48.3 Prior

France Manufacturing Purchasing Managers Index Preliminary For April 44.9 Vs. 46.9 Est.; 46.2 Prior

<a href="https://www.globenewswire.com/Tracker?data=DoqkUAnQT0K36GETdoDpEZBf9Fti-plTY2wG7QpNG3Fa51vlPx8BDWho7hFh8ZIILi7jfJ_qdDmugGk4v9tyq3aE1vJzhj4NyR_SFo1avkBqXA-4yyh7rM54vHz4wxFBH_EDY9-ch3EFWiyoQbYcYA==">nCino, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>), a pioneer in cloud banking for the global financial services industry, today announced that <a href="https://www.globenewswire.com/Tracker?data=fhG6E4csOlrOzGLDpxrfG0wHTVpSrUbb4Kk9mPiLc75ukgPgpacC80kGp4O-rTLEO-HjqqoJT7xLcfibKcPjoQ==">Together</a>, one of the UK's leading property lenders, has selected <a href="https://www.globenewswire.com/Tracker?data=DoqkUAnQT0K36GETdoDpESS0YzZmGD_x43n1I63tr5Rn-umHBrUc1Ri2uCb3oGDfzrGnhYYzlUUBt7RPKw48rMlnSoqB7eFhriJdQg7EFeGDHjioSY7Z2NwdFWm9wDJ9LgW94m775I5_NrDxFdHiB9DgQjnHwYVMmcS8szaqEyTq0fx70N9hbR9oZpd7xmsV40oX0TvrBzrUhrgNu2SSiA==">nCino's Cloud Banking Platform</a> to revolutionise and future-proof its business.

NCNO

UK Property Lender Together Tapped nCino to Revolutionise its Lending Business

Teledyne e2v, a Teledyne Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) company and global innovator of imaging solutions, is pleased to announce a new technology and design collaboration with <a href="https://www.airy3d.com/">Airy3D</a> (Montreal, Canada), a leading 3D vision solution provider. The first result of this partnership is the co-engineering of the recently announced <a href="https://imaging.teledyne-e2v.com/products/2d-cmos-image-sensors/topaz5d/">Topaz5D</a>&#x2122;, a low-cost, low power, passive, 2 megapixel global shutter sensor which produces 2D images and 3D depth maps. &nbsp;

Teledyne e2v and Airy3D Collaborate to Deliver Affordable 3D Vision Solutions

STGW

Reported Earlier, Stagwell Strengthens Asia Pacific Presence, Adds Indonesia's Leverate Group To Global Affiliate Program

Earnings

Grupo Aeroportuario Del Pacifico Q1 EPADS $2.586 Up From $2.553 YoY, Sales Ps.8.49B Up From Ps.8.34B YoY

Tesla&nbsp;and&nbsp;SpaceX&nbsp;CEO&nbsp;Elon Musk&nbsp;took aim at&nbsp;Social Security on Monday, calling it the &#8220;Biggest Ponzi scheme ever.&#8221; Social Security provides retirement income and helps millions of Americans qualify for Medicare.
What Happened:&nbsp;Musk was replying to a meme comparing Social Security to a Ponzi scheme (a fraudulent investment scheme). He added, &#8220;Maybe AI and robots will save it though.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/04/38368734/elon-musk-hits-back-at-australias-leader-amid-row-over-removal-of-violent-video-from-x-does-the-pm-t">Elon Musk Hits Back At Australia&#8217;s Leader Amid Row Over Removal Of Violent Video From X: &#8216;Does The PM Think He Should Have Jurisdiction Over All Of Earth?&#8217;</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Biggest ponzi scheme ever. Maybe AI and robots will save it though.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1782565870188789784?ref_src=twsrc%5Etfw">April 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
In the comments section, people were divided. While some said that many people who have never paid into Social Security, end up getting the benefits, others said that the tech billionaire was &#8220;badmouthing a system that is a primary means of survival for many elderly Americans.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Not to mention that prior to social security, many people had no choice but to work until death. I can see why that would be appealing to an apartheid billionaire. A Patriotic American, whose predecessors sacrificed so SOCSEC could exist? Not so much.
&mdash; Gaydolf Wokeler (@BrianDogeMiller) <a href="https://twitter.com/BrianDogeMiller/status/1782585462072463861?ref_src=twsrc%5Etfw">April 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Look up how many people who've never paid into Social Security receive it. Explain that one. Someone we know came from Canada after they retired, and because of their age, they were allowed to receive Social Security. The system is broken.
&mdash; Sherry Jurach (@SJurach) <a href="https://twitter.com/SJurach/status/1782586536997028111?ref_src=twsrc%5Etfw">April 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The long-term viability of Social Security is a major concern for many Americans. They <a href="https://www.benzinga.com/personal-finance/24/03/37541461/working-into-your-70s-nikki-haleys-bold-proposal-for-retirement-age">worry about its ability</a> to disburse full benefits in the future. According to the Social Security and Medicare Trustees Reports, by 2033 the fund will only be able to disburse 77% of the total scheduled benefits.
BlackRock CEO Larry Fink last month <a href="https://www.benzinga.com/markets/equities/24/03/37936320/larry-fink-warns-of-us-retirement-crisis-in-blackrocks-annual-letter-you-are-on-your-own">emphasized the urgency</a> of addressing the global &#8220;retirement crisis.&#8221; With medical advancements extending life expectancy, traditional approaches to retirement savings and working patterns may need significant reform.
While concerns exist, there&#8217;s also optimism. A <a href="https://www.benzinga.com/personal-finance/24/03/37919337/half-of-americans-now-optimistic-about-social-securitys-future-data-shows">2023 Gallup survey</a> shows that &#8220;Americans are more optimistic about the future of Social Security than they have been in recent years.&#8221; Among nonretired Americans, 50% expect to receive benefits, compared to 47% who don&#8217;t.
As of 2024, the <a href="https://www.benzinga.com/personal-finance/financial-advisors/24/01/36758328/this-is-the-age-most-americans-retire-and-how-to-know-whether-youre-on-track-">average retirement age</a> for retirees in the U.S. is 64, with workers expecting to retire at 66. The full retirement age is 67 for those born in 1960 or later
Check out more of Benzinga's Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next: <a href="https://www.benzinga.com/news/24/04/38349837/elon-musk-agrees-every-american-household-will-have-a-1-000-per-month-home-robot-in-7-years-time">Elon Musk Agrees Every American Household Will Have A $1,000-Per-Month Home Robot In 7 Years&#8217; Time</a>
Photo via Shutterstock

Tech

Elon Musk Calls Social Security The Biggest Ponzi Scheme Ever: 'Maybe AI And Robots Will Save It'

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Fear&#8221; zone on Monday.
U.S. stocks closed higher on Monday, with the S&amp;P 500 snapping a six-session losing streak.
On the economic data front, the Chicago Fed National Activity Index increased to +0.15 in March versus a revised reading of +0.09 in the previous month, topping market estimates of +0.09.
Shares of Zions Bancorporation, N.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) gained around 4% on Monday after the company reported upbeat earnings for its first quarter. Verizon Communications Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) stock fell around 5% on Monday after it reported fiscal first-quarter 2024 results.
All sectors on the S&amp;P 500 closed higher, with financial, utilities, and information technology stocks recording the biggest gains on Monday.
The Dow Jones closed higher by around 254 points to 38,239.98 on Monday. The S&amp;P 500 rose 0.87% at 5,010.60, while the Nasdaq Composite climbed 1.11% at 15,451.31 during Monday's session.
Investors are awaiting earnings results from Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) today.
At a current reading of 37.6, the index remained in the &#8220;Fear&#8221; zone on Monday, versus a prior reading of 32.3.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Also Read This: <a href="https://www.benzinga.com/news/24/04/38354671/top-2-consumer-stocks-that-may-implode-in-april">Top 2 Consumer Stocks That May Implode In April</a>

TSLA

ZION

Investor Optimism Improves, But Fear & Greed Index Remains In 'Fear' Zone

With U.S. stock futures trading slightly lower this morning on Tuesday, here are some stocks that may grab investor focus today:
<ul>
<li>Wall Street expects PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) to report quarterly earnings at $1.52 per share on revenue of $18.08 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. PepsiCo shares fell 1% to $174.79 in after-hours trading.</li>
<li>Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) posted better-than-expected earnings for its first quarter on Monday. The company said it sees second-quarter earnings of $2.07 per share. Packaging Corp shares fell 5.2% to $170.00 in the after-hours trading session.</li>
<li>Analysts are expecting General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) to post quarterly earnings at $2.14 per share on revenue of $41.88 billion. The company will release earnings before the markets open. GM shares fell 0.3% to $43.07 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Hibbett, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transaction. Hibbett shares gained 1.9% to close at $72.49 on Monday.</li>
<li>Analysts expect Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) to post quarterly earnings at 51 cents per share on revenue of $22.34 billion after the closing bell. Tesla shares fell 0.4% to $141.45 in after-hours trading.</li>
</ul>
Read More: <a href="https://www.benzinga.com/24/04/38355486/top-3-financial-stocks-that-could-blast-off-this-quarter">Top 3 Financial Stocks That Could Blast Off This Quarter</a>

Equities

General Motors, Tesla And 3 Stocks To Watch Heading Into Tuesday

Guidance

Novartis Now Expects 2024 Net Sales To Grow High Single To Low Double-Digit (Prior Mid-Single-Digit) And Core Operating Income To Grow Low Double-Digit To Mid-Teens (Prior High Single-Digit)

VLRS

Volaris 2024 Guidance, Anticipates ASM Growth (YoY) Of -16% to -18% And An EBITDAR Margin Of 32%-34% (Prior 31%-33%)

2024&nbsp;Guidance
For the&nbsp;second quarter&nbsp;of 2024, the Company expects:
<table align="center">
<tbody>
<tr>
<td>2Q&#39;24</td>
<td>2Q&#39;23&nbsp;(1)</td>
</tr>
<tr>
<td>2Q&#39;24&nbsp;Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>ASM growth (YoY)</td>
<td>~&nbsp;-18%</td>
<td>+18.1%</td>
</tr>
<tr>
<td>TRASM</td>
<td>$9.1&nbsp;to&nbsp;$9.2&nbsp;cents</td>
<td>$7.92&nbsp;cents</td>
</tr>
<tr>
<td>CASM ex fuel</td>
<td>$5.5&nbsp;to&nbsp;$5.6&nbsp;cents</td>
<td>$4.82&nbsp;cents</td>
</tr>
<tr>
<td>EBITDAR margin</td>
<td>31%&nbsp;to&nbsp;33%</td>
<td>27.1%</td>
</tr>
<tr>
<td>Average USD/MXN rate</td>
<td>Ps.17.30 to 17.50</td>
<td>Ps.17.72</td>
</tr>
<tr>
<td>Average U.S. Gulf Coast jet fuel price</td>
<td>$2.60&nbsp;to&nbsp;$2.70</td>
<td>2.29</td>
</tr>
<tr>
<td>(1) For convenience purposes, actual reported figures for 2Q&#39;23 are included.</td>
</tr>
</tbody>
</table>

Volaris Provides Q2 Guidance: Expects ASM (YoY) Of About -18%, TRASM Of $9.1-$9.2 Cents, CASM Excluding Fuel Of $5.5-$5.6 Cents, And An EBITDAR Margin Of 31%-33%

Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported quarterly earnings of $1.80 per share which beat the analyst consensus estimate of $1.67 by 7.78 percent. This is a 16.88 percent increase over earnings of $1.54 per share from the same period last year. The company reported quarterly sales of $11.829 billion which beat the analyst consensus estimate of $11.433 billion by 3.46 percent. This is a 8.68 percent decrease over sales of $12.953 billion the same period last year.

Earnings Beats

Novartis Q1 2024 Adj EPS $1.80 Beats $1.67 Estimate, Sales $11.829B Beat $11.433B Estimate

Hours after reports of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) <a href="https://www.benzinga.com/news/24/04/38361822/tesla-layoffs-hit-marketing-team-retracts-advertising-push">laying off its marketing team</a> in the U.S., CEO Elon Musk said the ads made by the team failed to impress him.
What Happened: The CEO concurred with an X user and Tesla enthusiast who said the ads made by the team were rather unimpressive and wrote, &#8220;Exactly. The ads were far too generic – could've been any car.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Exactly. The ads were far too generic – could've been any car.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1782436262881661053?ref_src=twsrc%5Etfw">April 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk&#8217;s comment comes on the heel of a Bloomberg report that the EV giant has removed its newly formed marketing team as part of the <a href="https://www.benzinga.com/news/24/04/38244436/breaking-tesla-said-to-be-laying-off-over-14-000-employees">10% companywide layoff </a>announced last week. The report noted that the entirety of the team in the U.S., including senior manager Alex Ingram, were eliminated. 
Trial And Error: Musk first expressed <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32439283/tesla-bulls-cheer-elon-musks-decision-to-try-some-advertising-it-could-be-amazingly">willingness to try traditional advertising</a> less than a year ago in May 2023. Until then, the company boasted of spending almost no money on advertising but became popular purely via word of mouth.
Since then, Tesla has attempted advertising on different platforms including YouTube, X, and even Meta Platforms&#8217; Instagram, and Facebook <a href="https://www.benzinga.com/news/24/03/37908129/facebook-isnt-lame-for-musk-anymore-tesla-rejoins-zuckerbergs-social-media-platform-after-ghosting-i">despite Musk&#8217;s past criticism of them</a>. 
However, in January, Tesla executives clarified during the fourth-quarter earnings call that while the lack of awareness impacted EV adoption, the company would not spend too much on advertising and marketing but instead spend it in areas and geographies where the company has low market share such as Japan. 
Analyst Take: Not all Tesla analysts favor this strategy of low advertising investment. The Future Fund Managing Partner Gary Black has often criticized Tesla&#8217;s attempts at driving sales via price cuts that weigh heavily on the company&#8217;s margins. Black recommends advertising instead. 
Even on Monday, Black reiterated that educating combustion engine vehicle owners on the perks of EVs via advertising is &#8220;badly needed&#8221; to drive sales. &#8220;Anyone can cut price. It's a blunt inefficient tool,&#8221; Black added. 
Anti-Tesla Advertising: While Musk has been sidestepping advertising, anti-Tesla crusaders have been going all in. 
The Dawn Project, <a href="https://www.benzinga.com/news/23/10/35125361/exclusive-dawn-projects-dan-odowd-warns-teslas-terrible-fsd-could-be-banned-blames-musk-for-coordina" target="_blank" rel="noreferrer noopener">founded by tech billionaire</a> Dan O'Dowd, released two ads at the Super Bowl championship earlier this year alleging that Tesla failed to act despite the group flagging multiple concerns about the safety of its full self-driving (FSD) driver assistance software and urged for a boycott of the company.
"When you buy a new Tesla you are financing and enabling Elon Musk to put a dangerous, unfinished, product on our public roads," O'Dowd <a href="https://www.benzinga.com/news/24/02/37085404/tesla-boycott-superbowl-ad-earns-regulators-ire-did-not-grant-permission-to-use-the-ntsb-seal">said in a statement</a> then. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by <a href="http://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next: <a href="https://www.benzinga.com/news/24/04/38351810/tesla-fsd-is-now-nearly-50-cheaper-than-when-elon-musk-called-it-very-low-just-under-a-year-ago">Tesla FSD Is Now Nearly 50% Cheaper Than When Elon Musk Called It &#8216;Very Low&#8217; Just Under A Year Ago</a>
Image made via pictures on Shutterstock

Elon Musk Admits Tesla Ads Were 'Far Too Generic' After Laying Off US Marketing Team: 'Could've Been Any Car'

Controladora Vuela (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $(0.18) by 261.11 percent. This is a 147.54 percent increase over losses of $(0.61) per share from the same period last year. The company reported quarterly sales of $768.000 million which beat the analyst consensus estimate of $694.633 million by 10.56 percent. This is a 5.06 percent increase over sales of $731.000 million the same period last year.

Controladora Vuela Q1 2024 GAAP EPS $0.29 Beats $(0.18) Estimate, Sales $768.000M Beat $694.633M Estimate

Gain Therapeutics Inc (GANX) is around the top of the Biotechnology industry according to InvestorsObserver. GANX received an overall rating of 85, which means that it scores higher than 85 percent of all stocks. Gain Therapeutics Inc also achieved a score of 96 in the Biotechnology industry, putting it above 96 percent of

Is Gain Therapeutics Inc (GANX) a Bad Choice in Biotechnology Tuesday?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Gain Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ganx-stock-quote/">GANX</a>) just reported results for the fourth quarter of 2023.<ul><li>Gain Therapeutics reported earnings per share of -29 cents. This was above the analyst estimate for EPS of -32 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/ganx-stock-earnings-gain-therapeutics-for-q4-of-2023/">GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023

Gain Therapeutics GAAP EPS of -$1.71 misses by $0.14, revenue of $0.05M misses by $0.25M

Gain Therapeutics (GANX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy...

Optimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson's Drug Candidate GT-02287

Gain Therapeutics Inc (GANX) is around the top of the Biotechnology industry according to InvestorsObserver. GANX received an overall rating of 63, which means that it scores higher than 63 percent of all stocks. Gain Therapeutics Inc also achieved a score of 73 in the Biotechnology industry, putting it above 73 percent of

Gain Therapeutics Inc (GANX) is down -11.50% in a Week, Should You Hold?

Gain Therapeutics (GANX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from...

Buy Rating Affirmed for Gain Therapeutics on Promising Parkinson's Treatment and Solid Financial Outlook

Gain Therapeutics gets new chief medical officer

NVCR, SBNY and VITL are among after hour movers

Gain Therapeutics names Gene Mack as CFO

Gain Therapeutics (GANX) has shared an update. Gene Mack has been appointed as the new Chief Financial Officer of Gain Therapeutics, Inc., effectiv...

Gain Therapeutics Welcomes New CFO Gene Mack

ALHC

CERO

GUTS

NVCR

PTLO

SBNY

TWKS

VITL

Analyst Ratings

Press Releases

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Gain Therapeutics' CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease

Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease

Management

Gain Therapeutics to Present at Public Ventures Discovery Day

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer